PN vs PDRN
Why They Are Not Interchangeable

The Naming Problem in the Polynucleotide Category

Open any aesthetic ingredient supplier’s catalogue and you will find the same material listed under several names, sometimes within a single document. PN. PDRN. Polynucleotide. Polydeoxyribonucleotide. Sodium DNA. Sometimes these are used correctly as distinct entries. Often they are not.

For a buyer, this is not a terminology quibble. A procurement specification is a document that has to survive translation, quotation, order confirmation, and goods receipt without drifting. If the product name is imprecise at the top of that chain, the imprecision propagates through every document downstream — and the point at which you discover the drift is usually the point at which the goods are already on your dock.

This guide covers what separates the two categories, how each is regulated, and how to use the naming question as a fast supplier-quality filter.

---

What Separates PN From PDRN

Both categories are derived from nucleic acids. That shared ancestry is what causes the confusion — but the two are differentiated in ways that matter for both documentation and classification.

PDRN — polydeoxyribonucleotide

PDRN is a relatively short-chain polynucleotide material, historically derived from a specific biological source material and processed into a defined size range. Its established commercial identity is as a specific, named material with a defined processing route rather than as a broad family. When you order PDRN, you are ordering a material with an expected size distribution and an expected source description.

PN — polynucleotide

PN is used as the broader family term for polynucleotide-based materials. A PN specification typically describes a polymeric nucleic-acid-derived material characterised by molecular size or size distribution, chain length, and source. Where PDRN refers to a specific, historically-sourced material, PN as a category encompasses a broader set of polynucleotide products.

The practical consequence for procurement is that a PN specification and a PDRN specification are not mutually substitutable. They describe materials whose characteristic parameters are established differently, and a Certificate of Analysis written for one does not confirm the other.

Procurement parameter	PDRN	PN
Term expands to	Polydeoxyribonucleotide	Polynucleotide
Category scope	Specific material with defined processing and size range	Broader family of polynucleotide-based materials
Characterisation emphasis	Defined size distribution and source description	Molecular size or size distribution and chain characteristics
Common supply formats	Injectable solution, ampoule	Injectable solution, ampoule, gel formats
Documentation focus	Source material and processing route	Molecular weight distribution and content
Typical buyer error	Ordering as a generic synonym for PN	Treating it as interchangeable with PDRN

Why the difference is not cosmetic

The two categories differ in molecular characterisation, in source material, and — where a regulatory decision has been made — in the specific product that was assessed. A regulator authorises a specific product with a specific characterisation, not a general category. That means a decision on one cannot be transferred to the other by assertion, and a supplier who offers to substitute one for the other is offering to change what your specification describes.

---

Regulatory Positioning: What You Can and Cannot Say

The regulatory picture for this family is more developed than it is for some other novel categories, but it is also more frequently misdescribed in supplier marketing. Being precise here protects the buyer.

United States

The FDA has not approved any PN or PDRN injectable product as a dermal filler or skin booster. The materials the agency has approved for use in dermal fillers are limited to:

• Hyaluronic acid
• Collagen
• Calcium hydroxylapatite
• Poly-L-lactic acid
• Polymethylmethacrylate microspheres

Polynucleotides and polydeoxyribonucleotides are not among them. Any supplier describing a PN or PDRN product as an FDA-approved filler or skin booster is stating something the FDA has not said. Separately, the FDA’s enforcement activity in adjacent novel-category segments — including warning letters issued on the basis that a product was an unapproved new drug and an unlicensed biological product — shows that the agency scrutinises this commercial space. Buyers should assume that regulatory attention in the broader novel-category segment will increase rather than decrease.

Korea

Korea’s Ministry of Food and Drug Safety (MFDS) has approved polynucleotide-based products through a medical device pathway. Korea is the largest single market for the category, and the existence of an approved pathway is a genuine positive indicator of product legitimacy.

The scope limit is what matters for buyers, and it is worth stating precisely: an MFDS authorisation is a Korean national authorisation. It is not a US approval, not an EU authorisation, and not a global one. A supplier who represents it as any of those things is not misreporting the Korean decision; they are misrepresenting what it covers. That is a different and equally serious problem.

European Union

In the EU, classification of a polynucleotide product depends on its intended purpose and the claims placed on the market with it. The EU framework distinguishes between cosmetic, medical device, and medicinal product regimes, and a product’s classification follows its intended purpose rather than its marketing budget. Buyers importing into the EU should establish in writing which regime the supplier believes applies to the specific product, and should be sceptical of a supplier who cannot answer.

Market context

The polynucleotide injectable category is commercially substantial and growing, with published market research placing it in the hundreds of millions of US dollars with double-digit projected growth through the early 2030s. This is context, not regulatory status. But it does support a planning assumption: a growing, concentrated category attracts regulatory scrutiny in proportion to its commercial weight.

---

Why Conflating the Terms Is a Red Flag

Any single documentation error can be a clerical slip. The reason PN/PDRN conflation deserves weight in a supplier evaluation is that it fails at the top of the document chain, where precision is cheapest to achieve.

Consider what a buyer actually relies on. The specification sheet defines what you are ordering. The purchase order, order confirmation, and invoice carry the product name forward. The Certificate of Analysis certifies a specific material. The label identifies the physical goods. If the category name in that chain is used loosely, then each downstream document inherits the ambiguity, and there is no point in the chain where it gets corrected — because every party is using the same loose term.

A second consideration is what the error reveals about the supplier’s process. A manufacturer producing a polynucleotide material runs a process in which the material’s size distribution, source, and processing route are controlled parameters. A supplier who cannot distinguish the categories in their own commercial documentation is either not the manufacturer, or is not close to the specification. Neither is what a buyer wants in a counterparty.

Three checks that surface the problem quickly

1. Ask the supplier to define both terms. A supplier who owns a genuine PN or PDRN product can define both accurately and distinguish them. A trader relaying a catalogue entry usually cannot.
2. Ask for a Certificate of Analysis that names the material precisely. If the CoA uses the terms interchangeably with the spec sheet, the documentation chain is not controlled.
3. Ask which category the product is, and which regulatory decision — if any — it relies on. The answer should name a specific product and a specific jurisdiction, or state plainly that no authorisation applies.

Check	Strong answer	Weak answer
Define PN and PDRN	Accurate, distinct definitions	“They are basically the same”
Material named on CoA	Exact category matching spec sheet	Terms used interchangeably
Regulatory basis	Names product and jurisdiction, or states none applies	Vague reference to “approved” or “certified”
Source and characterisation	Names source material and size distribution	No characterisation provided
Scope statement	States which market the authorisation applies to	Implies worldwide approval

---

Reading a PN or PDRN Specification Sheet

A specification sheet that supports procurement should contain the following. Judge it as a document: if a section is missing, that is information about the supplier.

• Exact material category, using the correct term — not a generic label.
• Molecular size or size distribution, stated numerically where applicable.
• Source material and processing description.
• Concentration in the applicable unit, with a tolerance where one exists.
• Volume and container format, matching the physical pack.
• Storage conditions and declared shelf life.
• Sterility and bacterial endotoxin reporting, with method and result.
• Regulatory classification and the market it applies to, or an explicit statement that none applies.
• Label and leaflet language, checked against your destination market.

For the Certificate of Analysis, the same principle applies as in any injectable category: measured numerical values against stated limits, a lot number matching the physical goods, and a dated quality release. A document that asserts compliance without reporting measurements is a specification sheet, not a lot record.

---

The Bottom Line for Buyers

PN and PDRN are two categories, not two spellings of one material. They differ in molecular characterisation and source, and they differ in which specific products have been assessed by which regulator in which market. The FDA has approved no PN or PDRN injectable filler or skin booster; Korea’s MFDS has authorised polynucleotide products under a medical device pathway, and that authorisation applies in Korea.

For procurement, the naming question is a fast and reliable filter. A supplier who distinguishes the categories precisely in their documentation is operating a controlled document chain, and that precision very often extends to the measured values and lot traceability you cannot see until after you order. A supplier who conflates them has told you, before you have spent anything, how the rest of the chain behaves.

If you are sourcing polynucleotide-format or PDRN-format products, request the classification and documentation package before committing to an order.